
Cullinan Oncology Inc
NASDAQ:CGEM

Fundamental Analysis


Revenue & Expenses Breakdown
Cullinan Oncology Inc
Balance Sheet Decomposition
Cullinan Oncology Inc
Current Assets | 275.9m |
Cash & Short-Term Investments | 265.5m |
Other Current Assets | 10.4m |
Non-Current Assets | 244.4m |
Long-Term Investments | 242.3m |
PP&E | 1.7m |
Other Non-Current Assets | 367k |
Free Cash Flow Analysis
Cullinan Oncology Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Cullinan Oncology Inc
Revenue
|
0
USD
|
Operating Expenses
|
-234.7m
USD
|
Operating Income
|
-234.7m
USD
|
Other Expenses
|
27.9m
USD
|
Net Income
|
-206.8m
USD
|
CGEM Profitability Score
Profitability Due Diligence
Cullinan Oncology Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Score
Cullinan Oncology Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
CGEM Solvency Score
Solvency Due Diligence
Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Cullinan Oncology Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CGEM Price Targets Summary
Cullinan Oncology Inc
According to Wall Street analysts, the average 1-year price target for
CGEM
is 29.453 USD
with a low forecast of 22.22 USD and a high forecast of 36.75 USD.
Dividends
Current shareholder yield for CGEM is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?